Pulmozyme® (dornase alfa) Co-pay and Financial Support

Genentech is here to help you get your prescribed medicine

Eligible commercially insured patients pay no more than $30 per month with the Pulmozyme Co-pay Card Program*

You may be eligible for the Pulmozyme Co-pay Card Program if you:

  • Have private insurance or insurance through an employer
  • Are taking Pulmozyme for an FDA-approved use
  • Are over the age of 18, or have a legal guardian over the age of 18 to manage the card
  • Do not have a government-funded health insurance plan (eg, Medicare, Medicare Advantage, Medicaid, TRICARE)
  • Are not receiving assistance from the Genentech® Access to Care Foundation (GATCF) or other charitable organizations
  • Do not reside in a state where co-pay cards are prohibited

The Co-pay Card Program covers any additional out-of-pocket costs for Pulmozyme, after you pay $30 for a 30-day supply, up to $10,000 per year, for most privately insured patients.

To learn more about the Pulmozyme Co-pay Card Program:

Call: 1-877-PZ4URCF

From 8 AM to 8 PM ET,
Monday through Friday

Find out which assistance option might be right for you by using our Patient Assistance Tool.

At Genentech Access Solutions, we are committed to making sure you get your prescribed medicine. Over the past 20 years, we have helped over 1.5 million patients get the various Genentech medicines they need.

If you are eligible, there may be options to help you pay for Pulmozyme:

  • Genentech co-pay cards*: Genentech offers the Pulmozyme Co-pay Card that may help eligible commercially insured patients with the out-of-pocket costs of Pulmozyme
  • Referrals to independent co-pay assistance foundations: Independent co-pay assistance foundations help patients with public health insurance or commercial health insurance
  • The Genentech® Access to Care Foundation, or GATCF§: GATCF helps people who don't have health insurance. It also helps people who have health insurance but have trouble paying for Pulmozyme. If you qualify for GATCF, you could receive Pulmozyme free of charge

To get started, complete a form called the PAN.

To learn more about how Pulmozyme Access Solutions can help:

Call: (800) 690-3023

From 9 AM to 8 PM ET,
Monday through Friday

Even if you have health insurance, you might feel concerned about the cost of your CF treatments

Download the Open Enrollment Brochure

Take a look at this brochure for tips on determining which health insurance plan is best for you. Then, when open enrollment seasonII arrives, you will have the chance to change your insurance plan based on your needs.

  • *This Co-pay Card is only available with a valid prescription and cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription. It is only valid for Pulmozyme and only valid in the United States and Puerto Rico. The Co-pay Card is not health insurance or a benefit plan. Patients are eligible as long as they continue to meet program eligibility criteria. Restrictions apply. Please visit www.PulmozymeCoPayCard.com for the full list of terms and conditions.
  • Patients must meet certain criteria.
  • Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech's endorsement or financial support. There may be other foundations to support the patient's disease state.
  • §To qualify for free medicine from GATCF, patients must meet certain criteria.
  • IIOpen enrollment dates can vary between employers. Make sure to check with your employer for exact opening and closing dates for your enrollment period.
  • PAN=Patient Authorization and Notice of Request for Transmission of Health Information to Genentech Access Solutions and Genentech® Access to Care Foundation.

Continue reading for Pulmozyme resources ›

Indication and Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

For additional Important Safety Information, please click here for the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF Care Team.